Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.55 |
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.48 |
| ▸ | NMT2 | O60551 | 2/20 | 0.46 |
| ▸ | NMT1 | P30419 | 2/20 | 0.46 |
| ▸ | NPY4R | P50391 | 4/20 | 0.45 |
| ▸ | NPY1R | P25929 | 2/20 | 0.45 |
| ▸ | NPY2R | P49146 | 2/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
| ▸ | FNTB | P49356 | 1/20 | 0.45 |
| ▸ | GNPAT | O15228 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17304351 | 1.00 | SLC6A5 (0.55) | SLC6A5NOD1FOLH1NMT2NMT1 | |
| SCHEMBL17304346 | 1.00 | SLC6A5 (0.55) | SLC6A5NOD1FOLH1NMT2NMT1 | |
| SCHEMBL7275349 | 1.00 | SLC6A5 (0.55) | SLC6A5NOD1FOLH1NMT2NMT1 | |
| SCHEMBL12971329 | 1.00 | SLC6A5 (0.55) | SLC6A5NOD1FOLH1NMT2NMT1 | |
| SCHEMBL12971402 | 0.99 | SLC6A5 (0.53) | SLC6A5NOD1FOLH1NMT2NMT1 | |
| SCHEMBL12971400 | 0.99 | SLC6A5 (0.53) | SLC6A5NOD1FOLH1NMT2NMT1 | |
| SCHEMBL17304348 | 0.90 | NOD1 (0.52) | SLC6A5NOD1FOLH1NPY4RNPY1R | |
| SCHEMBL17304352 | 0.90 | NOD1 (0.52) | SLC6A5NOD1FOLH1NPY4RNPY1R | |
| SCHEMBL17304354 | 0.90 | NOD1 (0.52) | SLC6A5NOD1FOLH1NPY4RNPY1R | |
| SCHEMBL17304345 | 0.90 | NOD1 (0.52) | SLC6A5NOD1FOLH1NPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111375066-B | Compositions and methods for treating cancer | 百欧肯治疗有限公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-115996741-A | CXCR4 inhibitors for the treatment of acute respiratory distress syndrome and viral infections | 百欧林纳克斯有限公司 | 2023-04-21 | — | — | CN | disclosed |
| US-11013704-B2 | Compounds supports hematopoietic stem cells and red blood cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3011961-B1 | 4F-BENZOYL-TN14003 FOR THE MOBILISATION OF HEMATOPOIETIC PROGENITOR CELLS IN VIEW OF TRANSPLANTATION | BIOKINE THERAPEUTICS LTD (IL) | 2020-11-11 | — | — | EP | disclosed |
| EP-3419645-B1 | METHOD OF SELECTING A TREATMENT REGIMEN IN ACUTE MYELOID LEUKEMIA (AML) | BIOLINERX LTD (IL) | 2020-09-02 | — | — | EP | disclosed |
| EP-3062809-B1 | A CXCR4 PEPTIDE INHIBITOR FOR USE IN TREATING ACUTE MYELOID LEUKEMIA WITH A FLT3 MUTATION | BIOKINE THERAPEUTICS LTD (IL) | 2020-07-08 | — | — | EP | disclosed |
| CN-111375066-A | Compositions and methods for treating cancer | 百欧肯治疗有限公司 | 2020-07-07 | — | — | CN | disclosed |
| US-20170304240-A1 | NOVEL COMPOUNDS SUPPORTS HEMATOPOIETIC STEM CELLS AND RED BLOOD CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-10-26 | — | — | US | disclosed |
| EP-2978439-B1 | A COMBINATION OF A CXCR4 ANTAGONIST AND CYTARABINE FOR USE IN TREATING MYELOID LEUKEMIA | BIOKINE THERAPEUTICS LTD (IL) | 2017-08-16 | — | — | EP | disclosed |
| WO-2015183545-A1 | NOVEL COMPOUNDS SUPPORTS HEMATOPOIETIC STEM CELLS AND RED BLOOD CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-12-03 | — | — | WO | disclosed |
| EP-2442822-B1 | PEPTIDE THERAPY FOR INCREASING PLATELET LEVELS | BIOKINE THERAPEUTICS LTD (IL) | 2014-03-05 | — | — | EP | disclosed |
| EP-1898943-B1 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | HADASIT MED RES SERVICE (IL) | 2012-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304240-A1 | NOVEL COMPOUNDS SUPPORTS HEMATOPOIETIC STEM CELLS AND RED BLOOD CELLS | EPOR, THPO, MCL1 | SLC6A5 4824/4885NOD1 4864/4885FOLH1 1193/4885 |
| US-11013704-B2 | Compounds supports hematopoietic stem cells and red blood cells | EPOR, THPO, MCL1 | SLC6A5 4711/4885NOD1 4866/4885FOLH1 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.